ASLAN Pharmaceuticals Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -4.63 | -100% |
| P/S |
|
4.41 | 33.76 | -86.93% |
|
|
| P/BV |
|
-3.98 | 4.82 | -182.63% |
|
|
| P/FCF |
|
0 | 61 | -100% |
|
|
| Ev/Ebitda |
|
-1.35 | -22.15 | -93.91% |
|
|
| Ev/S |
|
4.88 | 22.56 | -78.39% |
|
|
| Ev/FCF |
|
-1.26 | 68.78 | -101.83% |
|
|
| E/P |
|
0 | 0.0178 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-361.56 | 4.98 | -7364.69% | -589.16 | -38.63% |
| ROE |
|
332.81 | 9.61 | 3362.54% |
|
|
| ROA |
|
-179.56 | 0.3443 | -52258.59% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
-368.5 | -25.17 | 1364.04% |
|
|
| ROCE |
|
329.16 | 15.35 | 2044.33% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.6183 | -3.68 | -83.18% | -0.7229 | -14.47% |
| Nеt Debt/Ebitda |
|
-0.1284 | -3.44 | -96.26% |
|
|
| Debt/Ratio |
|
1.09 | 0.1985 | 448.81% |
|
|
| Debt/Equity |
|
0 | 1.66 | -100% |
|
|
| Debt/Net Income |
|
-0.6066 | 10.32 | -105.88% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5442 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2237 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9889 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4952 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5442 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
1/10
|
4.45 | -56.89 | -107.82% | ||
| Growth impulse Ebitda in 5 years |
|
2792.47 | -54.68 | -5206.93% | ||
| Growth impulse Net Income in 5 years |
|
2663.73 | -58.33 | -4666.66% | ||
| Growth impulse FCF in 5 years |
|
5304.5 | -49.48 | -10820.49% | ||
| Growth impulse EPS in 5 years |
|
1015.89 | -32.41 | -3234.5% |
IP Score
5.08/10
